How Long Does It Take to Start a First-in-Human Trial in Latin America? | bioaccess®

PRACTICAL GUIDE | 2026

From signed contract to first patient: realistic clocks for the fast corridor and the major markets.

By Julio G. Martinez-Clark

CEO, bioaccess®

Last verified: September 2026 | General information only—not legal or regulatory advice. Rules change frequently; confirm the strategy with qualified regulatory counsel.

How long does it take to start a first-in-human trial in Latin America? It is the most-asked timeline question in FIH vendor selection — and the honest answer is that there is no single clock. Sponsors ask three versions of it: “What is your quote for the start-up duration?” “What country do you propose for the quickest completion of the FIH study and data quality?” And “How can we speed up the timeline?” This post answers all three with the clocks we actually quote.

How long does it take to start a first-in-human trial in Latin America? The country-by-country clock

Latin America splits into two speed tiers. The fast corridor — Panama, Chile, El Salvador, and Costa Rica — activates in 15 to 45 days. The major markets — Mexico, Brazil, Colombia, and Argentina — typically need 6 to 9 months. Quote by pathway, not by continent.

What drives the startup clock? Four stages

Every country’s clock is the sum of the same four stages. The fast corridor is fast because each stage compresses — not because any stage is skipped.

• 1. Preparation and translation. Protocol, investigator’s brochure, informed consent, case report forms, insurance policy. The quality of the source documents sets the pace — a clean package translates and submits once.
• 2. Ethics committee cadence. How often the committee meets, and whether review runs through a hospital committee or a national body. Panama issues the ethics-submission ID in about 3 business days, with up to 30 days for requirements that rarely arrive.
• 3. Import permits. The investigational device must enter the country through formal, traceable importation. Import timelines fold into the startup clock — plan them as part of the pathway, not after it.
• 4. Parallel vs. sequential submission. In fast markets, the ethics committee and the regulator receive submissions in parallel, not one after the other. Parallel submission is a designed-in timeline accelerator, not a shortcut.

How can you speed up the timeline?

• Activate multi-site — ideally multi-country. Parallel programs in two countries hedge both timeline and recruitment risk; it is the single most effective accelerator.
• Run ethics and regulatory submissions in parallel wherever the pathway allows it.
• Submit a complete, translation-ready package the first time. Most startup delay is rework, not review.
• Pre-qualify KOLs during startup so investigator contracting does not gate first-patient-in.
• Use a CRO that has run the exact pathway before — unfamiliar teams generate the “requirements” that stall everyone else.

From activation to first patient: KOL qualification and enrollment modeling

KOL qualification — identifying, evaluating, and contracting the investigators who will actually enroll — takes 1 to 3 months and can run in parallel with regulatory startup. After approvals land, the first patient typically follows in about a month. For enrollment modeling, we are deliberately conservative: about 1 patient per month for a first-in-human, adjusted to the site’s real patient flow. Recruitment is managed weekly — site meetings every week, roadblocks cleared continuously, backup sites prequalified before they are needed.

Frequently asked questions

Q: Which Latin American country is fastest for a first-in-human trial?

A: Panama, Chile, El Salvador, and Costa Rica form the fast corridor at 15–45 days to activation. Panama is the documented extreme: about 15 days in a real program.

Q: Can you really have a trial activated in 30 days?

A: In the fast corridor, yes. The ethics-submission ID arrives in about 3 business days; requirements, when they come at all, rarely add meaningful time.

Q: What slows startup down in Brazil or Mexico?

A: Full agency review (ANVISA, COFEPRIS) plus ethics committee processes, larger dossiers, and import logistics. The trade-off is scale: deeper investigator pools and larger patient populations.

Q: Do ethics committee and regulator review happen at the same time?

A: In fast markets, yes — submissions run in parallel, which is a major reason the corridor is fast. In major markets the sequence is longer; design the pathway country by country.

Q: How long does KOL qualification take?

A: One to three months — and it should run during regulatory startup, not after it, so investigators are contracted when approvals land.

Q: How long does it take to start a first-in-human trial in Latin America if we need the fastest possible path?

A: Pick the fast corridor, activate multi-site (ideally multi-country), submit ethics and regulator in parallel, and pre-qualify KOLs during startup. That combination is how 15-day activations happen.

How long does it take to start a first-in-human trial in Latin America? Anywhere from 15 days to 9 months — and the difference is the country pathway you choose, the parallelism you design in, and the discipline of the submission. Ask for the clock by country, by stage, and in writing.

Talk with bioaccess® about your Latin America FIH strategy

Tell us your device, your patient population, and your target first-patient-in date. We will give you a country-by-country startup clock — prep, ethics, import, and enrollment — before you commit to anything.

Talk with bioaccess® about your Latin America FIH strategy

References

• bioaccess® operational data from first-in-human programs across Latin America, 2021–2026 (activation timelines, ethics cadence, KOL qualification, enrollment modeling). Last verified: September 2026.
• Country regulators referenced: Panama MINSA, Chile ISP, El Salvador, Costa Rica, Colombia INVIMA, Mexico COFEPRIS, Brazil ANVISA, Argentina ANMAT.